Literature DB >> 22698903

Efficacy of administration of coagulation factor XIII with definitive surgery for multiple intractable enterocutaneous fistulae in a patient with decreased factor XIII activity.

Susumu Saigusa1, Takeshi Yamamura, Koji Tanaka, Masaki Ohi, Aya Kawamoto, Minako Kobayashi, Yasuhiro Inoue, Masato Kusunoki.   

Abstract

Enterocutaneous fistulae (ECF) are challenging problem commonly encountered by surgeons and cause significant complications. They not only prolong hospital stay, but also restrict a patient's activities of daily living. The authors report a case of successful treatment of multiple intractable ECF in a patient with decreased coagulation factor XIII (FXIII) activity using intravenous FXIII treatment. A 74-year-old man with multiple ECF was referred. Although no factors involved in impaired wound were initially identified, he developed ECF after multiple surgical interventions with repeated wound dehiscence. FXIII activity was below the normal value. A definitive operation was performed and FXIII was administrated for 5 days postoperatively. There was no fistula recurrence and no other complications. Preoperative assessment of factors related to wound repair, such as FXIII activity, may be important for patients with wound dehiscence and subsequent fistula development and should be considered in patients who are resistant to standard treatments.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22698903      PMCID: PMC3063276          DOI: 10.1136/bcr.09.2010.3342

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  17 in total

1.  Management of enterocutaneous fistulas: 30-year clinical experience.

Authors:  Jieshou Li; Jian'an Ren; Weiming Zhu; Lu Yin; Jianming Han
Journal:  Chin Med J (Engl)       Date:  2003-02       Impact factor: 2.628

2.  Factor XIII (FXIII) and angiogenesis.

Authors:  R Dardik; J Loscalzo; A Inbal
Journal:  J Thromb Haemost       Date:  2005-08-26       Impact factor: 5.824

3.  Operative strategy in the treatment of enterocutaneous fistulas.

Authors:  G L Hill
Journal:  World J Surg       Date:  1983-07       Impact factor: 3.352

Review 4.  Physiopathology and regulation of factor XIII.

Authors:  A Ichinose
Journal:  Thromb Haemost       Date:  2001-07       Impact factor: 5.249

5.  An 11-year experience of enterocutaneous fistula.

Authors:  P Hollington; J Mawdsley; W Lim; S M Gabe; A Forbes; A J Windsor
Journal:  Br J Surg       Date:  2004-12       Impact factor: 6.939

6.  Clinical outcome and factors predictive of recurrence after enterocutaneous fistula surgery.

Authors:  A Craig Lynch; Conor P Delaney; Anthony J Senagore; Jason T Connor; Feza H Remzi; Victor W Fazio
Journal:  Ann Surg       Date:  2004-11       Impact factor: 12.969

7.  Reduced levels of coagulation factor XIII in patients with advanced tumor disease.

Authors:  P Born; F Lippl; K Ulm; P Gerein; C Lersch; F Eckel; G Fischer; W Sandschin; U Dlaska; M Classen
Journal:  Hepatogastroenterology       Date:  2000 Jan-Feb

Review 8.  Surgical management of high output enterocutaneous fistulae: a 24-year experience.

Authors:  Ariff A Haffejee
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2004-05       Impact factor: 4.294

9.  Prediction of mortality by logistic regression analysis in patients with postoperative enterocutaneous fistulae.

Authors:  D F Altomare; G Serio; O C Pannarale; L Lupo; N Palasciano; V Memeo; M Rubino
Journal:  Br J Surg       Date:  1990-04       Impact factor: 6.939

10.  Proximal diverting jejunostomy for compromised small bowel.

Authors:  M W Mulholland; J P Delaney
Journal:  Surgery       Date:  1983-03       Impact factor: 3.982

View more
  4 in total

1.  Effect of early administration of coagulation factor XIII on fistula after pancreatic surgery: the FIPS randomized controlled trial.

Authors:  Yoshinori Takeda; Yoshihiro Mise; Naoki Ishizuka; Sohei Harada; Brian Hayama; Yosuke Inoue; Takeaki Ishizawa; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2018-11-30       Impact factor: 3.445

2.  Dynamics of coagulation factor XIII activity after video-assisted thoracoscopic lobectomy for non-small cell lung cancer.

Authors:  Suguru Shirai; Yoshikane Yamauchi; Fumi Yokote; Takashi Sakai; Yuichi Saito; Yukinori Sakao; Masafumi Kawamura
Journal:  J Thorac Dis       Date:  2019-12       Impact factor: 2.895

3.  Rectovaginal fistula after low anterior resection for rectal cancer healed by nonoperative treatment.

Authors:  Shigenobu Emoto; Hiroaki Nozawa; Satomi Yoneyama; Koji Murono; Manabu Kaneko; Kazuhito Sasaki; Kensuke Otani; Takeshi Nishikawa; Toshiaki Tanaka; Keisuke Hata; Tomomichi Kiyomatsu; Kazushige Kawai; Kanako Omata; Tatsuki Noguchi; Koichi Masuda; Hiroki Sakata; Yusuke Tajima; Akio Hidemura; Hiroyuki Suzuki; Masahiro Ishimaru; Toshiaki Watanabe
Journal:  Int J Surg Case Rep       Date:  2017-10-18

Review 4.  The impact of acquired coagulation factor XIII deficiency in traumatic bleeding and wound healing.

Authors:  Christian Kleber; Armin Sablotzki; Sebastian Casu; Martin Olivieri; Kai-Martin Thoms; Johannes Horter; Felix C F Schmitt; Ingvild Birschmann; Dietmar Fries; Marc Maegele; Herbert Schöchl; Michaela Wilhelmi
Journal:  Crit Care       Date:  2022-03-24       Impact factor: 19.334

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.